Regulation & Compliance

Marga.ai is turning human judgment into a scalable AI, starting with a famed happiness expert. But can wisdom truly be coded without losing its soul?

In a novel proposal, IKE Tech asks the FDA to regulate its AI-powered compliance software, aiming to curb youth vaping with biometric and blockchain tech.

Eli Lilly's new once-daily oral GLP-1, Foundayo, is now on telehealth platform Ro, offering a convenient, needle-free alternative to injectable drugs.

Facing crippling compliance costs and advanced threats, small defense contractors get a new lifeline with Celerium's automated DIB CyberDome platform.

The Future Nutra Foundation launches to provide free, public data on supplement accuracy, releasing its first report on popular electrolyte products.

A new report reveals finance professionals who own crypto are far more optimistic and see less risk than their peers, pointing to a maturing market.

A new study reveals why GLP-1 drugs work for some and not others. 23andMe's research could personalize obesity treatment for millions of patients.

America First Credit Union hires legal and risk expert Jessica Graham, signaling a strategic move to navigate complex regulations and aggressive M&A growth.

As AI and automation reshape global tax, a new online certificate from IBFD and VU Amsterdam aims to equip professionals with crucial, future-proof skills.

As online reviews face a crisis of trust, a Bay Area company doubles down on a physical directory, betting that verified quality is worth its weight in paper.

With most OUD patients lacking access to care, a new grant funds research into payment models that reward results, not just services.

After a multi-year legal battle over a construction project ended in a total loss, Colleyville taxpayers are footing a $1.37 million bill.

The nation's top farm co-op faces mounting losses from biofuel rules and weak grain markets, signaling wider distress across the American heartland.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

Asher House Wellness becomes Lillie&Lee, leveraging its founder's viral rescue fame to build a transparent wellness empire for both pets and people.

Celebrating a decade of challenging norms, AESARA eyes its next chapter in global health, armed with AI, RWE, and a focus on complex diseases.

As companies spend billions on AI with little to show, new analytics platforms aim to measure what's actually working—and what's just a waste of money.

Former DARPA and NIWC Pacific leader Dr. Patrick Sims joins EverGlade, bringing insider expertise to the high-stakes world of federal R&D funding.

The wealth manager raids BlackRock, Morgan Stanley, and Deutsche Bank for top portfolio managers to bolster its strategic growth in key regional markets.

Tractive's new trackers for dogs and cats offer AI-powered health insights, moving beyond location to vitals. But how do they fare in a crowded market?